Teri Woodwick Sides serves as Senior Vice President, Chief Marketing Officer of the Company. Sides is an industry veteran, bringing over 27 years of medtech and healthcare experience. Prior to joining Surmodics, Teri served as Founder and Chief Executive Officer of Projectory, a consulting firm that provides strategic marketing services to med tech clients, ranging from start-ups to global businesses. Prior to Projectory, Sides was the Vice President of Marketing and Product Development for Arizant, Inc. Acting as the chief architect for product and market growth strategies, Teri led development of industry-leading products, including the world's first patient warming gown. Sides holds an MBA from the University of Minnesota's Carlson School of Management. She has more than eight patents granted and several pending.
As the Senior Vice President y Chief Marketing Officer of Surmodics, the total compensation of Teri Sides at Surmodics is $1,271,120. There are 2 executives at Surmodics getting paid more, with Gary Maharaj having the highest compensation of $2,343,630.
Teri Sides is 50, she's been the Senior Vice President y Chief Marketing Officer of Surmodics since 2018. There are 19 older and 1 younger executives at Surmodics. The oldest executive at Surmodics, Inc. is David Dantzker, 76, who is the Independent Director.
Teri's mailing address filed with the SEC is 9924, West 74th Street, Eden Prairie, Hennepin County, Minnesota, 55344, United States of America.
Over the last 21 years, insiders at Surmodics have traded over $26,204,565 worth of Surmodics stock and bought 19,725 units worth $436,251 . The most active insiders traders include Jeffrey C Smith, Gary R Maharaj y Value Lp Starboard Value Gp.... On average, Surmodics executives and independent directors trade stock every 34 days with the average trade being worth of $415,014. The most recent stock trade was executed by Joseph J. Stich on 21 August 2024, trading 21,285 units of SRDX stock currently worth $706,662.
surmodics partners with the world's leading and emerging medical device, diagnostic and life sciences companies to develop and commercialize innovative products designed to improve lives by enabling the detection and treatment of disease. following two recent acquisitions, the company is transforming its medical device business from being a provider of coating technologies, to offering whole-product solutions. throughout its transformation, surmodics’ mission remains: to improve the detection and treatment of disease by using our technology to provide solutions to difficult medical device and diagnostic challenges.
Surmodics executives and other stock owners filed with the SEC include: